Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9884140 | 1.00 | HRH3 (0.54) | HRH3HRH4 | |
| SCHEMBL605197 | 1.00 | HRH3 (0.54) | HRH3HRH4 | |
| Hydrochloric Acid SCHEMBL4125721 | 0.99 | HRH3 (0.53) | HRH3HRH4 | |
| Hydrochloric Acid SCHEMBL4131359 | 0.99 | HRH3 (0.53) | HRH3HRH4 | |
| SCHEMBL605905 | 0.87 | HRH4 (0.58) | HRH3HRH4 | |
| Hydrochloric Acid SCHEMBL4125602 | 0.86 | HRH4 (0.57) | HRH3HRH4 | |
| SCHEMBL602745 | 0.83 | HRH4 (0.36) | HRH3HRH4 | |
| SCHEMBL604463 | 0.82 | HRH4 (0.47) | HRH3HRH4 | |
| Hydrochloric Acid SCHEMBL4135714 | 0.82 | HRH4 (0.36) | HRH3HRH4 | |
| SCHEMBL603791 | 0.82 | HRH4 (0.47) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927555-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2015-01-06 | — | — | US | claimed |
| EP-2200595-B1 | THIENO-AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-20 | — | — | EP | claimed |
| US-20120270855-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | EDWARDS JAMES P (US) | 2012-10-25 | — | — | US | claimed |
| US-20120238544-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Timoneda, Jesús Joanós i | 2012-09-20 | — | — | US | claimed |
| US-20120214792-A1 | THIENO- ADN FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | EDWARDS JAMES P (US) | 2012-08-23 | — | — | US | claimed |
| US-20120208793-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Timoneda, Jesús Joanós | 2012-08-16 | — | — | US | claimed |
| US-8193178-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-05 | — | — | US | claimed |
| EP-2200595-A2 | THIENO-AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2010-06-30 | — | — | EP | claimed |
| WO-2009038673-A2 | THIENO-AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-26 | — | — | WO | claimed |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| EP-2382013-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| WO-2009038673-A2 | THIENO-AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-26 | — | — | WO | disclosed |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208793-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | HRH3 2/4885HRH4 1/4885 |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | HRH3 2/4885HRH4 1/4885 |
| US-20120238544-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | HRH3 2/4885HRH4 1/4885 |
| US-20120214792-A1 | THIENO- ADN FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | HRH3 2/4885HRH4 1/4885 |
| US-20120270855-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | HRH3 2/4885HRH4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.